Best Peptides for Cutting (2026 Beginner's Guide)

4. Tesamorelin (Solo) — for users who already have a GHRP

Best for: people who already run ipamorelin (or another GHRP) and want to add the strongest GHRH.

Tesamorelin alone still produces meaningful GH elevation — trial data describe it as the strongest GHRH analog on a per-mg basis, and it's the only one with phase III evidence for both fat-loss and lean-mass effects. Users already running ipamorelin or another GHRP commonly add tesamorelin separately rather than buying the blend.

Where solo tesa falls short of the blend: two separate vials, two separate draws, and the two peptides need to be timed tightly enough to overlap for the GH-pulse synergy described in published research. Community usage of solo tesa skews toward users who either already had ipamorelin on hand or wanted finer dose control on each component than a fixed blend allows.

Community reports cluster around the same waist-tightening and visceral-fat reduction trial subjects describe, with users commonly noting the protocol is easier to dial when both peptides are sourced separately.

Deep dive: Best Tesamorelin Vendors | Tesamorelin Results Timeline

Learn more about Tesamorelin

Dive deeper before comparing vendors

5. MK-677 (Ibutamoren) — the no-needle cutting option

Best for: users who avoid injection and accept the side-effect profile that comes with daily oral dosing.

MK-677 is the only oral compound on this list. Published research describes it activating the same ghrelin receptor as the GHRPs orally, raising GH and IGF-1 over a 24-hour window. The Nass et al. 2008 trial reported 1.6 kg fat-free mass gain over 12 months in older adults — a meaningful lean-mass preservation signal in a population the control arm was losing in.

The complication on a cut: MK-677 also raises appetite in trial subjects and community reports, which most cutters do not want. Community sources commonly describe MK-677 cuts as practical only in small deficits (250-500 kcal/day), where the extra hunger can be redirected toward hitting protein. For aggressive cuts, community usage typically describes a GHRH+GHRP instead.

Trial-documented trade-offs include water retention in weeks 1-4, sharp appetite increase, and measurable elevation in fasting glucose. Community sources commonly treat the 8-week and 12-week HbA1c checks as non-negotiable on an MK-677 cycle.

Deep dive: MK-677 Dosing Guide | MK-677 Peptide Page

Learn more about MK-677 (Ibutamoren)

6. AOD-9604 — the cheap adjunct

Best for: users layering a low-cost fat-mobilization adjunct on top of a GHRH+GHRP base.

Published research describes AOD-9604 as the C-terminal fragment of GH (residues 177-191), proposed to preserve the lipolytic activity of GH without the insulin-like effects of full GH. The human evidence base is thinner than vendor marketing typically suggests — phase II obesity trials reported modest weight loss that did not consistently hit statistical significance across endpoints.

Where AOD-9604 fits in community usage: as a low-cost adjunct stacked on top of a GHRH+GHRP cut. Community sources commonly describe it as well-tolerated and inexpensive, possibly accelerating subcutaneous abdominal fat loss when layered. Community usage as a standalone cutting peptide is rare.

Community reports cluster widely, which is itself a signal that responses are individual. Some users describe noticeable acceleration of localized fat loss; others self-report no perceived change versus the GHRH+GHRP base alone.

Deep dive: Best AOD-9604 Vendors | AOD-9604 Dosing Guide

Learn more about AOD-9604

7. 5-Amino-1MQ — the experimental metabolism oral

Best for: users already running an injectable GH stack who want to test a separate mechanism via a pill.

Published research describes 5-amino-1MQ as an NNMT (nicotinamide N-methyltransferase) inhibitor. The proposed mechanism in animal models is that NNMT inhibition frees up intracellular NAD+ and SAM, which preclinical research describes as raising metabolic rate and reducing adipose storage. Human data is limited.

Community usage typically describes 5-amino-1MQ as an experimental adjunct for the metabolism angle, not a primary cutting tool. The oral delivery is the practical appeal — community sources commonly describe it as a second-mechanism layer for users already on an injectable GH stack who want to add a non-injectable lever.

Community reports vary widely across short cycles and overlap heavily with the underlying GH-stack effects, which makes 5-amino-1MQ's standalone signal hard to isolate in self-reported timelines.

Deep dive: Best 5-Amino-1MQ Vendors | 5-Amino-1MQ Dosing Guide

Learn more about 5-Amino-1MQ

How Different Audiences Choose

Community usage and trial-evidence patterns map cleanly onto reader profiles. Here's how the picks above tend to break down across common audiences:

Bodybuilding contest-prep users with budget flexibility typically choose tesamorelin + ipamorelin. Phase III trial data describe it as the strongest body-composition signal on this list.

First-time cutters or budget-constrained users typically choose CJC-1295 + ipamorelin. Community sources commonly describe it as the most accessible cutting entry point.

Users on an existing GH stack with a fat-loss stall commonly layer cagrilintide on top — community usage describes it as a stalled-cut tool, not a base stack.

Users on a medical GLP-1 protocol who lift commonly add tesa + ipa or CJC + ipa for lean-mass support. Community usage describes the GLP-1 as the fat-loss anchor and the GHRH+GHRP as the lean-mass anchor.

Users who avoid injection are limited to MK-677 (oral). Community sources commonly describe it as practical only in small deficits given the appetite signal.

Users running an existing GHRH+GHRP base who want a low-cost adjunct sometimes add AOD-9604 for the lipolytic angle, or 5-amino-1MQ for the oral metabolism angle. Community usage describes both as adjuncts, not primary cutting tools.

For the broader fat-loss-specific ranking (not cutting-specific), see Best Peptides for Fat Loss. For the bulking counterpart, see Best Peptides for Bulking.

What Trial and Community Data Describe as Signals of Effect

Three signals appear consistently in published research and community sources, in this order:

Weeks 1-2: Sleep depth and appetite signal. Trial subjects and community sources commonly describe deeper sleep within the first 1-2 weeks of a GHRH+GHRP base. On layered cagrilintide or MK-677 protocols, community reports cluster around an appetite shift (suppression on cagrilintide, increase on MK-677) within the same window.

Weeks 4-8: Bloodwork. IGF-1 is the most-tracked biomarker in both trials and community protocols — published research describes a working GHRH+GHRP stack raising IGF-1 30-60% from baseline. Trial protocols also commonly tracked fasting glucose and HbA1c at 8-12 weeks because GH opposes insulin, and a subset of trial subjects developed measurable glucose elevation. Community sources commonly flag HbA1c rises of 0.3% or more as a dose-reduction or compound-switch threshold.

Weeks 6-16: Body composition. Trial subjects on tesamorelin commonly described visible waist-tightening at 4-6 weeks and confirmed visceral fat reduction at trial endpoints. Community reports across full 12-16 week cuts commonly describe strength holding or improving when protein and resistance training are maintained. Trial data does not support claims of steroid-scale transformations from cutting peptide stacks.

Running GH peptides without bloodwork is functionally running them blind. The trial-and-community standard is baseline IGF-1 plus a 4-week recheck and 8-12 week metabolic panel — that's how published research designs measured efficacy, and it's what community sources commonly treat as the minimum monitoring set.

Related Reading

Best Peptides for Muscle Growth — anchor GH peptide ranking

Best Peptides for Bulking — counterpart article

Best Peptides for Fat Loss — broader fat-loss ranking

Preserve Muscle on Semaglutide & Tirzepatide — for users on a medical GLP-1

Peptide Muscle Timeline — week-by-week expectations

Tesamorelin Dosing Guide — protocol detail

Cagrilintide vs Semaglutide — direct comparison

Peptide Coupons — Save Up to 50%

Exclusive discount codes — save up to 50% at top vendors

References

1

Falutz J, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2010;95(9):4291-4304.

20101189

2

Adrian S, et al. Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154-159.

31237318

3

Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA. 2014;312(4):380-389.

25038357

4

Bowers CY, et al. GH-releasing peptide acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982.

2108187

5

Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.

16352683

6

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.

9849822

7

Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;149(9):601-611.

18981485

8

Garvey WT, et al. Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025.

40544432